Bertolino, Arthur P
Novartis (Switzerland) · Novartis Institutes for BioMedical Research
2 papers on CoChat
Most cited papers
- Verified
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut
Inflammatory Bowel DiseasePsoriasis: Treatment and Pathogenesis
Cited by 1,547
- Verified
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
McInnes, I. B., Sieper, J., Braun, J., Emery, P., van der Heijde, D., Isaacs, J. D., Dahmen, G., Wollenhaupt, J., Schulze-Koops, H., Kogan, J., et al. (2014) · Annals of the Rheumatic Diseases
Spondyloarthritis Studies and TreatmentsPsoriasis: Treatment and Pathogenesis
Cited by 343
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free